Metformin Versus Insulin in Gestational Diabetes
Primary Purpose
Gestational Diabetes
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
metformin
insulin
Sponsored by
About this trial
This is an interventional treatment trial for Gestational Diabetes focused on measuring gestational diabetes, metformin, insulin
Eligibility Criteria
Inclusion Criteria:
- Mothers with gestational diabetes who had at least twice plasma glucose at fasting > 5.4 mmol/L and/or 1 hour postprandial value > 7.7 mmol/L at 24 to 32 gestational weeks
Exclusion Criteria:
- Fasting glucose > 7.0 mmol/L or 1 hour postprandial plasma glucose > 11.0 mmol/L or Glycosylated hemoglobin A1c (HbA1c) > 7.0%
- Renal, hepatic or cardiac failure
- Pregestational use of metformin
- Pregnancy with multiple fetuses
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Metformin
insulin
Arm Description
Metformin 500 mg 1-2 tablets twice daily according to plasma glucose values
NPH insulin once or twice daily and/or insulin lispro or aspart according to preprandial and postprandial glucose values
Outcomes
Primary Outcome Measures
Birth Weight Per Arm
birth weight adjusted for gestational weeks expressed as standard deviation units using data from Finnish fetal growth charts in normal pregnancies
Secondary Outcome Measures
Pregnancy Induced Hypertension Per Arm
Participants with pregnancy induced hypertension defined as blood pressure over 140/90 mmHg or increase in systolic blood pressure > 30 mmHg or diastolic blood pressure > 15 mmHg
Maternal Weight Gain Per Arm
Pre-eclampsia Per Arm
Mode of Delivery Per Arm
Gestational Weeks at Delivery Per Arm
Induction of Delivery Per Arm
Shoulder Dystocia Per Arm
Neonatal Hypoglycemia Per Arm
Neonatal Hyperbilirubinemia Per Arm
Apgar Score at 5 Min After Delivery Per Arm
Apgar score 0-10. 0-2 points from heart rate; 0-2 points for respiratory effort; 0-2 points for skin colour; 0-2 points for muscle tone; 0-2 points for reflex response. For all items the higher the value, the better the outcome
Neonate Transfer to Intensive Care Unit Per Arm
Child Outcome at 2 Years Per Arm
neuropsychological and motor skills testing
Full Information
NCT ID
NCT01240785
First Posted
November 3, 2010
Last Updated
November 21, 2014
Sponsor
Turku University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01240785
Brief Title
Metformin Versus Insulin in Gestational Diabetes
Official Title
Metformin Versus Insulin in Gestational Diabetes. A Randomized Controlled Single Center Trial.
Study Type
Interventional
2. Study Status
Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
June 2006 (undefined)
Primary Completion Date
January 2011 (Actual)
Study Completion Date
December 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Turku University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Gestational diabetes is traditionally treated with insulin. Metformin is a peroral drug used worldwide in the treatment of type 2 diabetes and also in a few studies on patients with gestational diabetes. The investigators aim is to compare insulin and metformin in the treatment of gestational diabetes. The investigators hypothesis is that there is no difference between insulin and metformin treated mothers in the main outcome criteria (birth weight, neonatal complications).
Detailed Description
Gestational diabetes is traditionally treated with insulin. Metformin is a peroral drug used worldwide in the treatment of type 2 diabetes and also in a few studies on patients with gestational diabetes. The investigators aim is to compare insulin and metformin in the treatment of gestational diabetes. The investigators hypothesis is that there is no difference between insulin and metformin treated mothers in the main outcome criteria (birth weight, neonatal complications). The study was performed as a randomized controlled trial in one center, Turku University hospital using the non-inferiority design in June 2006 - December 2010. The final study population consisted of altogether 217 women, of whom 110 received metformin and 107 insulin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gestational Diabetes
Keywords
gestational diabetes, metformin, insulin
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
221 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Metformin
Arm Type
Active Comparator
Arm Description
Metformin 500 mg 1-2 tablets twice daily according to plasma glucose values
Arm Title
insulin
Arm Type
Active Comparator
Arm Description
NPH insulin once or twice daily and/or insulin lispro or aspart according to preprandial and postprandial glucose values
Intervention Type
Drug
Intervention Name(s)
metformin
Other Intervention Name(s)
Diformin retard 500 mg
Intervention Description
metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
Intervention Type
Drug
Intervention Name(s)
insulin
Other Intervention Name(s)
Protaphane, Humalog
Intervention Description
subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
Primary Outcome Measure Information:
Title
Birth Weight Per Arm
Description
birth weight adjusted for gestational weeks expressed as standard deviation units using data from Finnish fetal growth charts in normal pregnancies
Time Frame
delivery
Secondary Outcome Measure Information:
Title
Pregnancy Induced Hypertension Per Arm
Description
Participants with pregnancy induced hypertension defined as blood pressure over 140/90 mmHg or increase in systolic blood pressure > 30 mmHg or diastolic blood pressure > 15 mmHg
Time Frame
up to on the average 40 weeks of gestation
Title
Maternal Weight Gain Per Arm
Time Frame
up to on the average 40 weeks of gestation
Title
Pre-eclampsia Per Arm
Time Frame
up to on the average 40 weeks of gestation
Title
Mode of Delivery Per Arm
Time Frame
delivery
Title
Gestational Weeks at Delivery Per Arm
Time Frame
delivery
Title
Induction of Delivery Per Arm
Time Frame
delivery
Title
Shoulder Dystocia Per Arm
Time Frame
delivery
Title
Neonatal Hypoglycemia Per Arm
Time Frame
0-24 h after delivery
Title
Neonatal Hyperbilirubinemia Per Arm
Time Frame
0-3 days after delivery
Title
Apgar Score at 5 Min After Delivery Per Arm
Description
Apgar score 0-10. 0-2 points from heart rate; 0-2 points for respiratory effort; 0-2 points for skin colour; 0-2 points for muscle tone; 0-2 points for reflex response. For all items the higher the value, the better the outcome
Time Frame
5 minutes after delivery
Title
Neonate Transfer to Intensive Care Unit Per Arm
Time Frame
0-5 days after delivery
Title
Child Outcome at 2 Years Per Arm
Description
neuropsychological and motor skills testing
Time Frame
2 years after birth
10. Eligibility
Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Mothers with gestational diabetes who had at least twice plasma glucose at fasting > 5.4 mmol/L and/or 1 hour postprandial value > 7.7 mmol/L at 24 to 32 gestational weeks
Exclusion Criteria:
Fasting glucose > 7.0 mmol/L or 1 hour postprandial plasma glucose > 11.0 mmol/L or Glycosylated hemoglobin A1c (HbA1c) > 7.0%
Renal, hepatic or cardiac failure
Pregestational use of metformin
Pregnancy with multiple fetuses
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tapani Rönnemaa, MD, PhD
Organizational Affiliation
Professor, Chief Physician
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
34059525
Citation
Huhtala MS, Ronnemaa T, Pellonpera O, Tertti K. Cord serum metabolome and birth weight in patients with gestational diabetes treated with metformin, insulin, or diet alone. BMJ Open Diabetes Res Care. 2021 May;9(1):e002022. doi: 10.1136/bmjdrc-2020-002022.
Results Reference
derived
PubMed Identifier
32652973
Citation
Huhtala MS, Tertti K, Juhila J, Sorsa T, Ronnemaa T. Metformin and insulin treatment of gestational diabetes: effects on inflammatory markers and IGF-binding protein-1 - secondary analysis of a randomized controlled trial. BMC Pregnancy Childbirth. 2020 Jul 11;20(1):401. doi: 10.1186/s12884-020-03077-6.
Results Reference
derived
PubMed Identifier
30227169
Citation
Huhtala MS, Tertti K, Pellonpera O, Ronnemaa T. Amino acid profile in women with gestational diabetes mellitus treated with metformin or insulin. Diabetes Res Clin Pract. 2018 Dec;146:8-17. doi: 10.1016/j.diabres.2018.09.014. Epub 2018 Sep 15.
Results Reference
derived
PubMed Identifier
26439816
Citation
Pellonpera O, Ronnemaa T, Ekblad U, Vahlberg T, Tertti K. The effects of metformin treatment of gestational diabetes on maternal weight and glucose tolerance postpartum--a prospective follow-up study. Acta Obstet Gynecol Scand. 2016 Jan;95(1):79-87. doi: 10.1111/aogs.12788. Epub 2015 Nov 8.
Results Reference
derived
PubMed Identifier
24633859
Citation
Tertti K, Laine K, Ekblad U, Rinne V, Ronnemaa T. The degree of fetal metformin exposure does not influence fetal outcome in gestational diabetes mellitus. Acta Diabetol. 2014 Oct;51(5):731-8. doi: 10.1007/s00592-014-0570-6. Epub 2014 Mar 16.
Results Reference
derived
Learn more about this trial
Metformin Versus Insulin in Gestational Diabetes
We'll reach out to this number within 24 hrs